¸Þµð¾÷

´ëÇк´¿ø Çѹ溴¿ø
Á¾ÇÕº´¿ø ³ëÀκ´¿ø
°Ô½ÃÆÇ
°Ç°­Á¤º¸
º´¿ø¾à±¹Á¤º¸
Èú¸µ½ºÅ丮
Áúº´Á¤º¸
ÀǾàÇ°Á¤º¸
ÀÇÇм­Àû
ÀÓ´ëºÐ¾ç¸Å¸Å
¿¬¼ö°­ÁÂ
±³À°Á¤º¸
¸ÞµðÅå
´ëÇк´¿ø Á¾ÇÕº´¿ø Çѹ溴¿ø Ä¡°úº´¿ø ÇÑÀÇ¿ø ³ëÀÎÀü¹®º´¿ø º¸°Ç¼Ò
¼­¿ï ºÎ»ê ÀÎõ ´ë±¸ ´ëÀü ±¤ÁÖ ¿ï»ê °æ±â °­¿ø ÃæºÏ Ãæ³² °æºÏ °æ³² ÀüºÏ Àü³² Á¦ÁÖ ¼¼Á¾
Ä¡°ú ¾È°ú ÇǺΰú ¼ºÇü¿Ü°ú »êºÎÀΰú ºñ´¢±â°ú ¿Ü°ú ³»°ú Á¤Çü¿Ü°ú À̺ñÀÎÈÄ°ú ¼Ò¾Æ°ú ¾à±¹

¸ñ·Ï ¼öÁ¤ »èÁ¦

(¿Â¶óÀÎ) 2021 ´ëÇÑÁ¶Ç÷¸ð¼¼Æ÷À̽ÄÇÐȸ ±¹Á¦Çмú´ëȸ (ICBMT 2021 Virtual) - 8¿ù 26ÀÏ (1ÀÏÂ÷) : 2021-08-26

ÃßõÇϱâ
¿¬¼ö°­Á À̹øÁÖ BEST
 
(¿Â¶óÀÎ) 2021 ´ëÇÑÁ¶Ç÷¸ð¼¼Æ÷À̽ÄÇÐȸ ±¹Á¦Çмú´ëȸ (ICBMT 2021 Virtual) - 8¿ù 26ÀÏ (1ÀÏÂ÷) : 2021-08-26
±³À°ÀÏÀÚ : 2021-08-26
±³À°Àå¼Ò : ¿Â¶óÀΠ 
±³À°ÁÖÁ¦ : (¿Â¶óÀÎ) 2021 ´ëÇÑÁ¶Ç÷¸ð¼¼Æ÷À̽ÄÇÐȸ ±¹Á¦Çмú´ëȸ (ICBMT 2021 Virtual) - 8¿ù 26ÀÏ (1ÀÏÂ÷)
ÁÖÃÖ±â°ü : ´ëÇÑÁ¶Ç÷¸ð¼¼Æ÷À̽ÄÇÐȸ
´ã´çÀÚ : À±ÁöÇö
¿¬¶ôó : 070-4895-6129  
À̸ÞÀÏ : bmt@kams.or.kr      
±³À°Á¾·ù : ³»°ú, ¼Ò¾Æû¼Ò³â°ú, Áø´Ü°Ë»çÀÇÇаú      
Âü¼®¿¹»óÀοø : 600¸í
Èñ¸ÁÆòÁ¡ : 6Á¡  
Áö¿ª : ¼­¿ïƯº°½Ã
±³À°½Ã°£ : 7 ½Ã°£ 10ºÐ  
¼¼ºÎ¼ö°­·á : 20,000¿ø      
ºñ°í       

±¸ºÐ ¿ùÀÏ °­ÀǽǠ½Ã°£ ±³À°Á¦¸ñ  °­»ç¸í(¼Ò¼Ó) Çʼö°ú¸ñ
±³À°½Ã°£ 08-26 CH A 09:30~10:00 NGS-based MRD Monitoring Pre- and Post-Allogeneic HSCT for AML  Michael Heuser(MHH Hospital) 
±³À°½Ã°£ 08-26 CH A 10:00~10:30 Conditioning Intensity of Allogeneic Transplantation for AML with MRD  Christopher S. Hourigan(NIH) 
±³À°½Ã°£ 08-26 CH A 10:40~11:10 Engineering and Design for Next Generation CAR-T Cells  Sham Mailankody(MSKCC) 
±³À°½Ã°£ 08-26 CH A 11:20~11:50 Machine Learning Research for Hematopoietic Stem Cell Transplantation  Yasuyuki Arai(Kyoto University) 
±³À°½Ã°£ 08-26 CH A 11:50~12:20 Current Statistical Issues in Hematopoietic Cell Transplantation  Haesook T. Kim(Dana-Farber Cancer Institute) 
±³À°½Ã°£ 08-26 CH B 12:40~13:20 Optimizing Stem Cell Mobilization in Patients with Multiple Myeloma Undergoing Autologous Stem Cell Transplantation  Thomas Martin(University of California San Francisco) 
±³À°½Ã°£ 08-26 CH A 13:30~14:30 Risk factors and outcomes of cytomegalovirus infection in children post cord blood transplantation with focus on impact of graft-versus-host disease and immunosuppressants  Eun Sang Yi(Korea University Guro Hospital) 
±³À°½Ã°£ 08-26 CH A 14:40~15:10 High Throughput Single Cell Analysis in AML  Koichi Takahashi(MDACC) 
±³À°½Ã°£ 08-26 CH A 15:10~15:40 Therapeutic Implications in AML using Prospective Genomic Profiling  Omar Abdel-Wahab(MSKCC) 
±³À°½Ã°£ 08-26 CH A 15:40~16:10 Clonal Hematopiesis of Indeterminate Potential in Transplantation  Kyoung Ha Kim(Soonchunhyang University Hospital) 
±³À°½Ã°£ 08-26 CH A 16:30~17:00 FLT3 Inhibitor Maintenance Therapy after Allogeneic HSCT in FLT3 Mutated AML  Richard T. Maziarz(Oregon Health and Science University) 
±³À°½Ã°£ 08-26 CH A 17:00~17:30 Maintenance Therapy (Hypomethylating Agents, Bcl2-Inhibitor, Check Point Inhibitors, and Other Novel Drugs) after Allogeneic HSCT in AML and MDS  Tapan Kadia(MDACC) 
±³À°½Ã°£ 08-26 CH A 17:30~18:00 Treatment Strategies after Allogeneic HSCT in Relapsed ALL  Ik-Chan Song(Chungnam National University College of Medicine) 
ÆÄ¿ö¸µÅ© ±¤°íµî·Ï
ÀÌ °Ô½Ã¹°À» ÃßõÇÕ´Ï´Ù.
¸Þµð¾÷
" (¿Â¶óÀÎ) 2021 ´ëÇÑÁ¶Ç÷¸ð¼¼Æ÷À̽ÄÇÐȸ ±¹Á¦Çмú´ëȸ (ICBMT 2021 Virtual) - 8¿ù 26ÀÏ (1ÀÏÂ÷) : 2021-08-26""ÀÇ ÀÌ¿ëÈı⳪ Ãßõ´ñ±ÛÀ» ³²°Ü À¯¿ëÇÑ Á¤º¸·Î °øÀ¯ÇսôÙ. ^^
¡å
ÀÌ °Ô½Ã¹°À» ÃßõÇÕ´Ï´Ù.
 
¸ñ·Ï ¼öÁ¤ »èÁ¦
ÀÌÀü±Û (¿Â¶óÀÎ) 2021 ´ëÇÑÁ¶Ç÷¸ð¼¼Æ÷À̽ÄÇÐȸ ±¹Á¦Çмú´ëȸ (ICBMT 2021 Virtual) - 8¿ù 27ÀÏ (2ÀÏÂ÷) : 2021-08-27
´ÙÀ½±Û (¿Â¶óÀÎ) Á¦19ȸ ±è¾È°úº´¿ø ½ÉÆ÷Áö¾ö : 2021-08-22
¹øÈ£ Á¦¸ñ Ãßõ Á¶È¸ µî·ÏÀÏ
228 ¼­¿ï 2018³âµµ ´ëÇѺñ¸¸ÇÐȸ ±¹Á¦Çмú´ëȸ(ICOMES 2018) - 09/08 : 2018-09-08 0 616 2018-07-28
227 ¼­¿ï 2018³â À»Áö´ëÇб³ À»Áöº´¿ø À̺ñÀÎÈÄ°ú °³¿øÀÇ ¿¬¼ö°­Á : 2018-09-08 0 1,273 2018-07-28
226 ¼­¿ï 2018³â ´ëÇѳëÀθ¶ÃëÅëÁõÇÐȸ Çмú´ëȸ : 2018-09-08 0 619 2018-07-28
225 ºÎ»ê µ¿¾Æ´ëÇб³ÀÇ·á¿ø ½ÉÀüµµ Äܼ­Æ®(Arrhythmia in intecsive care units) : 2018-09-08 0 846 2018-07-28
224 ¼­¿ï ´ëÇÑ´ëÀåÇ×¹®ÇÐȸ International Colorectal Research Summit 2018 : 2018-09-08 0 439 2018-07-28
223 °æºÏ °æ»óºÏµµ µ¿ºÎ±Ç¿ª Çмú´ëȸ : 2018-09-08 0 556 2018-07-28
222 ¼­¿ï Á¦8ȸ ´ë»ç¼º°ñÁúȯ¿¬±¸È¸ ½ÉÆ÷Áö¾ö : 2018-09-08 0 524 2018-07-28
221 ¼­¿ï °­µ¿°æÈñ´ëÇб³ ½Å°æ°ú ¿¬¼ö°­Á : 2018-09-08 0 445 2018-07-28
220 ¼­¿ï ¼­¿ï´ëÇб³º´¿ø Á¦28ȸ ¼­¿ï ºñ´¢±â°úÇÐ ½ÉÆ÷Áö¿ò : 2018-09-08 0 401 2018-07-28
219 ÀÎõ Á¦3ȸ ÀÎÇϴ뺴¿ø ¼Ò¾Æû¼Ò³â°ú ±³À°°­Á : 2018-09-08 0 876 2018-07-28
218 ¼­¿ï Á¦ 19ȸ ´ëÇÑÅõ¼®Çùȸ Ãß°è ½ÉÆ÷Áö¿ò : 2018-09-08 1 705 2018-07-28
217 ¼­¿ï ´ëÇѽÉÀåÇÐȸ EP Review Course 2018-2 : 2018-09-08 0 959 2018-07-28
216 ÀüºÏ 2018³â Á¦29ȸ ´ëÇÑ°£ÇÐȸ Ãß°è Single Topic Symposium ¹× ÃÊÀ½ÆÄ Hands-on : 2018-09-08 0 400 2018-07-28
215 ÀÎõ 2018³â ±¹Á¦¼º¸ðº´¿ø °³¿øÀÇ ¿¬¼ö°­Á : 2018-09-08 0 558 2018-07-28
214 ÀÎõ °¡ÃµÀÇ´ë±æº´¿ø È£½ºÇǽº ¿ÏÈ­ÀÇ·á Á¤Âø°ú È®´ë¸¦ À§ÇÑ ÀÎõÁö¿ª¾Ï¼¾ÅÍ ½ÉÆ÷Áö¿ò : 2018-09-08 0 1,238 2018-07-28
1391 | 1392 | 1393 | 1394 | 1395 | 1396 | 1397 | 1398 | 1399 | 1400
 
Ä¿¹Â´ÏƼ
°Ô½ÃÆÇ
°Ç°­Á¤º¸
º´¿ø¾à±¹
Èú¸µ½ºÅ丮
Áúº´Á¤º¸
ÀǾàÇ°Á¤º¸
ÀÇÇм­Àû
ÀÓ´ë¸Å¸Å
¿¬¼ö°­ÁÂ
±³À°Á¤º¸
º´¿øȨÆäÀÌÁö
¸ÞµðÅå
ÇÑÀÇ¿ø
¼ºÇü¿Ü°ú
Ä¡°ú
¾È°ú
¿©¼ºº´¿ø
³»°ú
Á¤Çü¿Ü°ú
ÇǺΰú
¼Ò¾Æ°ú
À̺ñÀÎÈÄ°ú
ºñ´¢ÀÇÇаú
¿ä¾çº´¿ø
ÀçÈ°ÀÇÇаú
µ¿¹°º´¿ø
±âŸº´ÀÇ¿ø
Ãë¾÷°ü·Ã
Áö¿ø¼­¾ç½Ä
¼­·ù¾ç½Ä
¸Þµð¾÷ ¸ð¹ÙÀÏÀ¥
¸Þµð¾÷